Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
$4.65
+5.4%
$4.25
$4.14
$350.00
$39.10M0.399,135 shs39,045 shs
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
$1.99
-3.4%
$2.45
$0.91
$3.82
$129.71M-0.22234,643 shs256,077 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.04
-8.6%
$6.11
$3.90
$15.00
$83.39M0.69884,481 shs847,165 shs
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$47.10
-5.6%
$55.66
$4.77
$240.00
$137.35M3.1150,823 shs61,577 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
+4.75%+12.50%+9.43%+32.04%+0.23%
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
-2.83%-6.36%-13.45%-23.99%+116.84%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-26.96%-38.22%+27.85%+38.57%-46.82%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-3.84%+1.18%-7.21%-22.40%+790.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
$4.65
+5.4%
$4.25
$4.14
$350.00
$39.10M0.399,135 shs39,045 shs
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
$1.99
-3.4%
$2.45
$0.91
$3.82
$129.71M-0.22234,643 shs256,077 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.04
-8.6%
$6.11
$3.90
$15.00
$83.39M0.69884,481 shs847,165 shs
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$47.10
-5.6%
$55.66
$4.77
$240.00
$137.35M3.1150,823 shs61,577 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
+4.75%+12.50%+9.43%+32.04%+0.23%
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
-2.83%-6.36%-13.45%-23.99%+116.84%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-26.96%-38.22%+27.85%+38.57%-46.82%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-3.84%+1.18%-7.21%-22.40%+790.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.25
Hold$10.00115.05% Upside
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
2.86
Moderate Buy$7.20261.81% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-17.22% Downside
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.60
Moderate Buy$163.00246.07% Upside

Current Analyst Ratings Breakdown

Latest ATHE, CNTB, SPRB, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Initiated CoverageBuy$123.00
6/16/2026
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
Initiated CoverageBuy$10.00
6/9/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Initiated CoverageBuy$135.00
6/5/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Reiterated RatingSell (D-)
6/1/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Lower Price TargetBuy$200.00 ➝ $150.00
5/27/2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
Reiterated RatingOutperform
5/26/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
UpgradeHold (C-)Hold (C)
5/26/2026
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
Initiated CoverageBuy$6.00
5/26/2026
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
Initiated CoverageBuy$6.00
5/21/2026
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
Initiated CoverageOverweight$4.00
5/21/2026
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
Initiated CoverageOverweight$4.00
(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/A$3.10 per shareN/A
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
$60K2,088.17N/AN/A$0.75 per share2.65
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.33$1.00 per share6.01$2.75 per share2.20
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$4.91M26.38N/AN/A$39.72 per share1.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
-$7.87MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
-$55.48M-$1.15N/AN/AN/AN/A-122.29%-97.07%8/12/2026 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4513.429.29N/A2.94%23.89%12.47%9/3/2026 (Estimated)
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$38.97M-$36.60N/AN/AN/AN/A-155.40%-101.67%8/13/2026 (Estimated)

Latest ATHE, CNTB, SPRB, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$7.9340-$8.94-$1.0060-$8.94N/AN/A
5/12/2026Q1 2026
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
-$0.29-$0.34-$0.05-$0.34N/A$0.02 million
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
3/31/2026Q4 2025
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/AN/AN/AN/AN/A
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.203.31%N/A44.44%3 Years
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
N/AN/AN/AN/AN/A

Latest ATHE, CNTB, SPRB, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.052.12%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
N/A
21.97
N/A
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
0.01
3.23
3.23
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
0.16
4.67
4.67

Institutional Ownership

CompanyInstitutional Ownership
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
2.14%
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
58.72%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
91.71%

Insider Ownership

CompanyInsider Ownership
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
38.80%
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
22.60%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
4.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alterity Therapeutics Limited - Sponsored ADR stock logo
ATHE
Alterity Therapeutics
108.87 million5.43 millionNot Optionable
Connect Biopharma Holdings Limited Sponsored ADR stock logo
CNTB
Connect Biopharma
11062.96 million48.73 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
202.75 million2.63 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alterity Therapeutics stock logo

Alterity Therapeutics NASDAQ:ATHE

$4.65 +0.24 (+5.44%)
Closing price 04:00 PM Eastern
Extended Trading
$4.74 +0.09 (+1.94%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Connect Biopharma stock logo

Connect Biopharma NASDAQ:CNTB

$1.99 -0.07 (-3.40%)
Closing price 04:00 PM Eastern
Extended Trading
$2.03 +0.04 (+2.21%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$6.04 -0.57 (-8.62%)
Closing price 04:00 PM Eastern
Extended Trading
$5.90 -0.14 (-2.24%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Spruce Biosciences stock logo

Spruce Biosciences NASDAQ:SPRB

$47.10 -2.80 (-5.61%)
Closing price 04:00 PM Eastern
Extended Trading
$48.86 +1.76 (+3.73%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.